Familial Defective Apolipoprotein B-100 and Increased Low-Density Lipoprotein Cholesterol and Coronary Artery Calcification in the Old Order Amish
- 8 November 2010
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 170 (20) , 1850-1855
- https://doi.org/10.1001/archinternmed.2010.384
Abstract
Background: Elevated low-density lipoprotein cholesterol (LDL-C) levels are a major cardiovascular disease risk factor. Genetic factors are an important determinant of LDL-C levels. Methods: To identify single nucleotide polymorphisms associated with LDL-C and subclinical coronary atherosclerosis, we performed a genome-wide association study of LDL-C in 841 asymptomatic Amish individuals aged 20 to 80 years, with replication in a second sample of 663 Amish individuals. We also performed scanning for coronary artery calcification (CAC) in 1018 of these individuals. Results: From the initial genome-wide association study, a cluster of single nucleotide polymorphisms in the region of the apolipoprotein B-100 gene (APOB) was strongly associated with LDL-C levels (P < 10(-68)). Additional genotyping revealed the presence of R35002, the mutation responsible for familial defective apolipoprotein B-100, which was also strongly associated with LDL-C in the replication sample (P < 10(-36)). The R35002 carrier frequency, previously reported to be 0.1% to 0.4% in white European individuals, was 12% in the combined sample of 1504 Amish participants, consistent with a founder effect. The mutation was also strongly associated with CA Cin both samples (P < 10(-6) in both) and accounted for 26% and 7% of the variation in LDL-C levels and CAC, respectively. Compared with non-carriers, R35002 carriers on average had LDL-C levels 58 mg/dL higher, a 4.41-fold higher odds(95% confidence interval, 2.69-7.21) of having detectable CAC, and a 9.28-fold higher odds (2.93-29.35) of having extensive CAC (CAC score >= 400). Conclusion: The R35002 mutation in APOB is a major determinant of LDL-C levels and CAC in the Amish.This publication has 41 references indexed in Scilit:
- Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervixGynecologic Oncology, 2009
- ADAM9 is highly expressed in renal cell cancer and is associated with tumour progressionBMC Cancer, 2008
- The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart StudyAmerican Heart Journal, 2008
- Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women StudyHuman Molecular Genetics, 2006
- Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cellsExperimental Cell Research, 2006
- Effect of Lipid Modification on Progression of Coronary CalcificationJournal of the American Society of Nephrology, 2005
- The disintegrin domain of ADAM9: a ligand for multiple β1 renal integrinsBiochemical Journal, 2005
- Oxidative and Osmotic Stress Signaling in Tumor Cells Is Mediated by ADAM Proteases and Heparin-Binding Epidermal Growth FactorMolecular and Cellular Biology, 2004
- The Molecular Mechanism for the Genetic Disorder Familial Defective Apolipoprotein B100Journal of Biological Chemistry, 2001